Kane Biotech Inks Agreement with XSONX to Distribute Wound Hygiene System in Many Countries
Kane Biotech inks agreement with XSONX to distribute wound hygiene system in Canada, Australia, New Zealand & GCC countries
Overview
Kane Biotech Inc, a biotechnology company engaged in the research, development and commercialization of technologies and products to prevent and remove microbial biofilms, announced that it has signed an exclusive five years distribution agreement with a medical device company based in Charlotte, North Carolina, XSONX LLC to distribute XSONX’s Wound Hygiene System in Canada, Australia, New Zealand and the Gulf Cooperation Council (GCC) countries (the Territories).
XSONX Wound Hygiene System
The XSONX Wound Hygiene System is a cordless vibrational debridement tool which safely cleans and debrides chronic and contaminated wounds.
Words from the CEO: Kane Biotech
“The XSONX Wound Hygiene System is a proven contributor to chronic wound healing and will nicely complement Kane’s revyve product line,” said Marc Edwards, president & CEO.
“I’m excited about this opportunity to partner with XSONX and to make their debridement tool widely available to wound care professionals via our distribution network.”
Kane’s Work Post Aggrement
Kane Biotech will be introducing XSONX to Canadian practitioners starting on October 18, 2024 at the Wounds Canada National Hybrid Conference in conjunction with its revyve antimicrobial wound gel and revyve antimicrobial wound gel spray products.
Words from the CEO: XSONX
“According to recently released consensus documents, 60 per cent of wounds in the US are under debrided. I suspect this may be even higher in Canada and other international markets, making XSONX an important tool for practitioners,” said Dr. Wade Farrow, founder and CEO of XSONX.
“Kane’s dedication to quality and its growing international distribution network makes them our ideal partner.”
About Biotech Inc.
Kane has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by Kane’s own biofilm research expertise and acquired from leading research institutions.
DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of Kane Biotech Inc.
Kane is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB venture market under the symbol KNBIF.